DK3210973T3 - Heteroarylforbindelser til behandling af oftalmiske sygdomme - Google Patents

Heteroarylforbindelser til behandling af oftalmiske sygdomme Download PDF

Info

Publication number
DK3210973T3
DK3210973T3 DK15853151.7T DK15853151T DK3210973T3 DK 3210973 T3 DK3210973 T3 DK 3210973T3 DK 15853151 T DK15853151 T DK 15853151T DK 3210973 T3 DK3210973 T3 DK 3210973T3
Authority
DK
Denmark
Prior art keywords
treatment
ophthalmic diseases
heteroaryl compounds
heteroaryl
compounds
Prior art date
Application number
DK15853151.7T
Other languages
English (en)
Inventor
Yoshihiro Banno
Masahiro Kamaura
Kazuaki Takami
Koichiro Fukuda
Shigekazu Sasaki
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of DK3210973T3 publication Critical patent/DK3210973T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/38—One oxygen atom attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK15853151.7T 2014-10-24 2015-10-22 Heteroarylforbindelser til behandling af oftalmiske sygdomme DK3210973T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014217770 2014-10-24
PCT/JP2015/079782 WO2016063933A1 (ja) 2014-10-24 2015-10-22 複素環化合物

Publications (1)

Publication Number Publication Date
DK3210973T3 true DK3210973T3 (da) 2021-02-08

Family

ID=55760964

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15853151.7T DK3210973T3 (da) 2014-10-24 2015-10-22 Heteroarylforbindelser til behandling af oftalmiske sygdomme

Country Status (38)

Country Link
US (4) US10214498B2 (da)
EP (2) EP3848353A1 (da)
JP (2) JP6588027B2 (da)
KR (1) KR102490156B1 (da)
CN (2) CN107108506B (da)
AR (1) AR104342A1 (da)
AU (2) AU2015336480B2 (da)
BR (1) BR112017007138A2 (da)
CA (1) CA2965465C (da)
CL (1) CL2017000944A1 (da)
CO (1) CO2017003699A2 (da)
CR (1) CR20170160A (da)
CY (1) CY1123842T1 (da)
DK (1) DK3210973T3 (da)
DO (1) DOP2017000098A (da)
EA (1) EA033446B1 (da)
EC (1) ECSP17026687A (da)
ES (1) ES2848999T3 (da)
HR (1) HRP20210320T1 (da)
HU (1) HUE053443T2 (da)
IL (2) IL285105B2 (da)
LT (1) LT3210973T (da)
MA (2) MA53568A (da)
MX (2) MX2017004629A (da)
MY (1) MY183209A (da)
PE (1) PE20170669A1 (da)
PH (1) PH12017500747A1 (da)
PL (1) PL3210973T3 (da)
PT (1) PT3210973T (da)
RS (1) RS61504B1 (da)
SG (1) SG11201702312UA (da)
SI (1) SI3210973T1 (da)
SM (1) SMT202100082T1 (da)
TN (1) TN2017000097A1 (da)
TW (2) TWI703131B (da)
UA (1) UA121871C2 (da)
WO (1) WO2016063933A1 (da)
ZA (1) ZA201703344B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108506B (zh) * 2014-10-24 2022-06-21 武田药品工业株式会社 杂环化合物
CA3057087A1 (en) 2017-03-20 2018-09-27 The Broad Institute, Inc. Compounds and methods for the treatment of parasitic diseases
EP3638239A4 (en) 2017-06-15 2021-03-10 Belite Bio, Inc METHOD OF TREATMENT OF RBP4-RELATED DISEASES WITH TRIAZOLOPYRIDINES
WO2018232154A1 (en) 2017-06-15 2018-12-20 Belite Bio, Inc Methods of treating metabolic diseases with fused bicyclic pyrazoles
US12440486B2 (en) 2018-08-01 2025-10-14 The Trustees Of Columbia University In The City Of New York RBP4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout
CN111690695A (zh) * 2020-05-19 2020-09-22 浙江工业大学 3-苯氨基丙羟肟酸的酶促微流控在线合成方法
CN111690698A (zh) * 2020-05-19 2020-09-22 浙江工业大学 两步串联流动合成3-（苯并[d][1,3]二氧-5-氨基）丙羟肟酸的方法
EP4340701A4 (en) * 2021-05-21 2025-04-09 Belite Bio, LLC Biomarkers for age-related macular degeneration
WO2022256301A1 (en) * 2021-06-01 2022-12-08 Stargazer Pharmaceuticals, Inc. Methods and compounds for treating subjects with stargardt disease
CN116286900B (zh) * 2022-10-28 2024-04-26 昆明理工大学 一种乙酸渗透酶A基因RkAcpa及其应用
CN116019791B (zh) * 2022-12-28 2025-12-16 浙江工业大学台州研究院 二苯醚类化合物在制备β-葡萄糖醛酸苷酶抑制剂中应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625970A (en) 1968-04-17 1971-12-07 Cutter Lab 1-(disubstituted phenyl or benzyl)-1h-indazol-3-yloxyacetic acid
US5239080A (en) 1989-02-08 1993-08-24 Takeda Chemical Industries, Ltd. Oxazole compounds and their use as antidiabetic and bone-reduction inhibitory agents
EP0440183A1 (en) * 1990-02-01 1991-08-07 Takeda Chemical Industries, Ltd. Oxazole compounds, their production and use
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
AU1285499A (en) 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
WO2001025228A1 (en) 1999-10-07 2001-04-12 Tadeka Chemical Industries, Ltd. Amine derivatives
ES2225252T3 (es) 1999-11-10 2005-03-16 Takeda Chemical Industries, Ltd. Compuestos n-heterociclicos de 5 miembros con actividad hipoglucemica e hipolipidemica.
GB0020351D0 (en) 2000-08-17 2000-10-04 Catalyst Biomedica Ltd Treatment of hyperproliferative diseases
DE10149568A1 (de) 2001-10-08 2003-04-24 Consequence Gmbh Verfahren zur Sequenzanalyse von Polypeptiden
WO2003042204A1 (en) 2001-10-19 2003-05-22 Takeda Chemical Industries, Ltd. Amine derivative
US20040214788A1 (en) 2003-03-11 2004-10-28 Raj Madhwa H.G. Treatment of prostate cancer
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
JP4767850B2 (ja) 2003-08-20 2011-09-07 エミスフィアー テクノロジーズ インコーポレイテッド グルカゴン様ペプチド（ｇｌｐ）−１化合物またはメラノコルチン４受容体（ｍｃ４）アゴニストペプチドの経口デリバリーのための化合物、方法および製剤
EP1692521A1 (en) 2003-12-11 2006-08-23 Beth Israel Deaconess Medical Center, Inc. Rbp4 in insulin sensitivity/resistance, diabetes, and obesity
WO2005120583A2 (en) 2004-06-14 2005-12-22 Wisconsin Alumni Research Foundation Method for preventing or treating cardiac hypertrophy
KR100862930B1 (ko) 2004-06-23 2008-10-13 시리온 테라퓨틱스, 인크. 레티닐 유도체를 사용하여 안 증상을 치료하기 위한 방법및 조성물
US20080033053A1 (en) 2004-07-22 2008-02-07 Wolfgang Curt D Cross-Reference To Related Applications
US7947267B2 (en) 2004-10-08 2011-05-24 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
MX2008016167A (es) 2006-06-22 2009-02-10 Sirion Therapeutics Inc Metodos y composiciones para el tratamiento de condiciones oftalmicas via modulacion de actividad de megalina.
US20090005381A1 (en) 2007-06-26 2009-01-01 Philip Manton Brown Methods of treating serotonin-mediated diseases and disorders
AU2008268409B2 (en) 2007-06-26 2013-12-05 Lexicon Pharmaceuticals, Inc. Compositions comprising tryptophan hydroxylase inhibitors
US7973079B2 (en) 2007-09-27 2011-07-05 Revision Therapeutics, Inc. Methods and compounds for treating retinol-related diseases
WO2009042444A2 (en) 2007-09-27 2009-04-02 Sirion Therapeutics, Inc. Methods and compounds for treating retinol-related diseases
EP2202223B1 (en) * 2007-10-18 2017-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound as blood rbp4 lowering agent
US8541388B2 (en) 2008-05-22 2013-09-24 Isis Pharmaceuticals, Inc. Methods for modulating expression of RBP4
BRPI0913291A2 (pt) * 2008-05-30 2019-01-15 Takeda Pharmaceuticals Co composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto
CA2758587A1 (en) * 2009-04-13 2010-10-21 Irm Llc Compositions and methods for modulating retinol binding to retinol binding protein 4 (rbp4)
EP2419413B1 (en) * 2009-04-16 2016-11-23 Takeda Pharmaceutical Company Limited Derivatives of n-acyl-n'-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes
WO2011059776A2 (en) 2009-10-28 2011-05-19 Revision Therapeutics, Inc Prophylaxis of skin cancer with retinamides
AU2010327936B2 (en) 2009-12-11 2015-08-20 Nono Inc. Agents and methods for treating ischemic and other diseases
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
EP2642998B1 (en) 2010-11-24 2020-09-16 The Trustees of Columbia University in the City of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
RS58718B1 (sr) 2011-05-12 2019-06-28 Proteostasis Therapeutics Inc Regulatori proteostaze
GB201205679D0 (en) 2012-03-30 2012-05-16 Dyson Technology Ltd A hand held appliance
WO2013166041A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Transthyretin ligands capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular
WO2014134127A1 (en) 2013-02-26 2014-09-04 Northeastern University Cannabinergic nitrate esters and related analogs
WO2014160409A1 (en) 2013-03-14 2014-10-02 The Trustees Of Columbia University In The City Of New York Rbp4 antagonists for the treatment of age-related macular degeneration and stargardt disease
WO2014153643A1 (en) 2013-03-26 2014-10-02 The University Of British Columbia Compositions and methods for use thereof in the treatment of aniridia
JP2017508798A (ja) 2014-03-07 2017-03-30 ザ ジョンズ ホプキンス ユニバーシティ ヒストンリジン特異的デメチラーゼ（ｌｓｄ１）およびヒストンデアセチラーゼ（ｈｄａｃ）の阻害剤
PE20171239A1 (es) 2014-10-24 2017-08-24 Bristol Myers Squibb Co Derivados de carbazol
AR102426A1 (es) 2014-10-24 2017-03-01 Bristol Myers Squibb Co Compuestos de indolcarboxamida como inhibidores de btk
CN107108506B (zh) 2014-10-24 2022-06-21 武田药品工业株式会社 杂环化合物
US11040976B2 (en) 2015-04-24 2021-06-22 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof
US10189797B2 (en) 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use

Also Published As

Publication number Publication date
IL285105B (en) 2022-11-01
IL251695A0 (en) 2017-06-29
US10975043B2 (en) 2021-04-13
MX2017004629A (es) 2017-06-30
IL251695B (en) 2021-08-31
PH12017500747B1 (en) 2017-10-30
IL285105B2 (en) 2023-03-01
TN2017000097A1 (en) 2018-07-04
CN107108506A (zh) 2017-08-29
UA121871C2 (uk) 2020-08-10
SI3210973T1 (sl) 2021-04-30
US20190119225A1 (en) 2019-04-25
JP2020007347A (ja) 2020-01-16
US10214498B2 (en) 2019-02-26
RS61504B1 (sr) 2021-03-31
MY183209A (en) 2021-02-18
EP3210973A4 (en) 2018-04-25
US10544111B2 (en) 2020-01-28
PT3210973T (pt) 2021-02-12
CA2965465A1 (en) 2016-04-28
PE20170669A1 (es) 2017-06-06
SMT202100082T1 (it) 2021-03-15
CR20170160A (es) 2017-06-15
AU2020204426B2 (en) 2022-02-03
CA2965465C (en) 2023-08-01
HRP20210320T1 (hr) 2021-04-30
AU2015336480B2 (en) 2020-04-02
TWI749661B (zh) 2021-12-11
EP3210973B1 (en) 2020-12-02
PH12017500747A1 (en) 2017-10-30
TW202042805A (zh) 2020-12-01
KR102490156B1 (ko) 2023-01-18
TWI703131B (zh) 2020-09-01
SG11201702312UA (en) 2017-05-30
PL3210973T3 (pl) 2021-06-28
JP6588027B2 (ja) 2019-10-09
MA39688A (fr) 2017-08-30
AU2015336480A2 (en) 2017-06-01
AR104342A1 (es) 2017-07-12
CL2017000944A1 (es) 2018-01-12
WO2016063933A1 (ja) 2016-04-28
EA033446B1 (ru) 2019-10-31
JPWO2016063933A1 (ja) 2017-08-03
IL285105A (en) 2021-08-31
ECSP17026687A (es) 2017-09-29
KR20170067791A (ko) 2017-06-16
ES2848999T3 (es) 2021-08-13
MA53568A (fr) 2022-02-23
EP3210973A1 (en) 2017-08-30
TW201714876A (zh) 2017-05-01
CY1123842T1 (el) 2022-05-27
JP6995094B2 (ja) 2022-02-21
EP3848353A1 (en) 2021-07-14
HUE053443T2 (hu) 2021-06-28
US20210340114A1 (en) 2021-11-04
US20200157062A1 (en) 2020-05-21
CN115197160A (zh) 2022-10-18
BR112017007138A2 (pt) 2017-12-26
EA201790912A1 (ru) 2017-09-29
CN107108506B (zh) 2022-06-21
MX2021001188A (es) 2021-04-19
US20180237404A1 (en) 2018-08-23
MA39688B1 (fr) 2021-02-26
ZA201703344B (en) 2018-08-29
LT3210973T (lt) 2021-03-25
AU2015336480A1 (en) 2017-05-25
CO2017003699A2 (es) 2017-07-28
AU2020204426A1 (en) 2020-07-23
DOP2017000098A (es) 2017-07-15

Similar Documents

Publication Publication Date Title
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3728271T3 (da) Makrocykliske forbindelser til behandling af sygdomme
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3245206T3 (da) Pyrazinforbindelser til behandling af infektionssygdomme
DK3169328T3 (da) Quinolinderivater til behandling af inflammationssygdomme
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3492632T3 (da) Metoder til behandling af lithiumholdige materialer
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3851537T5 (da) Behandling af hyperbilirubinæmi
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3148529T3 (da) Forbindelser til behandling af hjernecancer
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3097085T3 (da) Benzoxazinonderivater til behandling af hudsygdomme
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
HUE053443T2 (hu) Heteroaril vegyületek szembetegségek kezelésére
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK3204398T3 (da) Fremgangsmåder til fraseparering af gemcitabin-phosphat diastereoisomerer
DK3164716T3 (da) Fremgangsmåde til diagnosticering af neurodegenerative sygdomme
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
DK3430143T3 (da) Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme
DK3578562T3 (da) L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme
DK3302573T3 (da) Sammensætning til behandlingen af hjernelæsioner
DK3209295T3 (da) Fremgangsmåder til behandling af øjenlidelser